Skip to main content

Thyroid Cancer clinical trials at UC Davis
1 research study open to eligible people

  • A Study of Experimental Cabozantinib Compared to Placebo For Differentiated Thyroid Cancer

    open to eligible people ages 16 years and up

    The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy.

    Sacramento, California and other locations

Last updated: